This issue will bring you up to date on the impact of Psoriasis and recent developments in drug therapy.
• Psoriasis is recognized as an immunemediated, chronic, systemic inflammatory condition.
• About 80% of patients with mild to moderate psoriasis can be managed well with topical medications.
• Corticosteroids are the cornerstone of topical therapy.
Psoriasis is the most common autoimmune condition in the US, affecting 7.5 million people. It is a complex, genetically linked disease; 1 in every 3 patients with psoriasis has a relative with the condition. The human and economic tolls are significant. Patients with psoriasis have lower quality of life scores, along with increased occurrences of depression, anxiety and suicidal ideation. In the US, more than $63 million is spent annually in direct healthcare costs for psoriasis.
Currently, there is no cure; however, a variety of treatments (topical, systemic, phototherapy) are available to manage symptoms, minimize disease progression, and improve quality of life. Since the early 2000s, research into the immunopathogenesis of psoriasis has led to the development of biologic agents that target specific components of the immune system. Despite the availability of multiple treatments, patients with psoriasis in the US are often under treated, or untreated. Untreated or under treated psoriasis leads to disseminated disease and potentially, to joint impairment in the form of psoriatic arthritis (PsA), which causes pain and stiffness of affected joints.
While psoriasis treatment guidelines recommend that trained specialty providers prescribe systemic therapies for patients with this disease, community practitioners should have a sufficient knowledge base to monitor treatment. Frequent patient interactions allow community practitioners, including pharmacists and nurse practitioners, to play an important role in psoriasis management. This issue will review basic information about cutaneous psoriasis and summarize various treatments so practitioners can better manage and educate patients...
- Pharmacists, Nurse Practitioners, Clinical Nurse Specialists, and Registered Nurses
This CE activity was developed by The Rx Consultant, a publication of Continuing Education Network, Inc.
CE activities for Pharmacists and Pharmacy Technicians:
This continuing education (CE) activity meets the requirements of all state boards of pharmacy for approved continuing education hours. CE credit is automatically reported to CPE Monitor.
CE activities for Nurse Practitioners and Clinical Nurse Specialists:
This continuing education activity meets the requirements of:
The American Nurses Credentialing Center (ANCC) for formally approved continuing education (CE) hours, and CE hours of pharmacotherapeutics.
The American Academy of Nurse Practitioners Certification Program (AANPCP) for acceptable, accredited CE.
This is a pharmacotherapeutics/pharmacology CE activity.
Continuing Education Network, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Requirements for CE Credit
- Discuss the epidemiology and contributing factors for the development of psoriasis.
- Describe psoriasis symptoms and how body surface area and the Psoriasis Area Severity Index (PASI) are used in assessing psoriasis severity.
- List commonly used topical treatments. Counsel patients regarding administration, side effects, and precautions.
- Compare and contrast systemic treatments used for psoriasis, including effectiveness, side effects, and precautions.
Celia P. MacDonnell,, BS Pharmacy, PharmD
Brief Bio : Celia P. MacDonnell, BS Pharmacy, PharmD is a Clinical Professor at the College of Pharmacy, University of Rhode Island. She is also an Adjunct Associate Professor of Family Medicine at the Alpert Medical School at Brown University. Her teaching, practice and research interests are in diseases of the eye and skin, and interprofessional education.
The CE Activity developed by The Rx Consultant